

BIOCON GROUP

FACT SHEET

Mar - 2024

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 24	Q4 FY 23	Variance %
<u>INCOME</u>			
Generics	719	744	-3%
Biosimilars	2,358	2,102	12%
Novel Biologics	-	19	0%
Research services	917	994	-8%
Inter-segment	(76)	(86)	-11%
Revenue from operations #	3,917	3,774	4%
Other income	49	155	-69%
TOTAL REVENUE	3,966	3,929	1%
<u>EXPENDITURE</u>			
Material & Power costs	1,417	1,343	5%
Staff costs	532	529	1%
Research & Development expenses*	246	342	-28%
Other expenses	806	563	43%
Manufacturing, staff & other expenses	3,001	2,777	8%
EBITDA	964	1,152	-16%
Interest & Finance charges	227	248	-9%
Depreciation & Amortisation	407	364	12%
Share of loss / (profit) in JV / Associate, net	3	40	-93%
PBT	328	500	-34%
Exceptional item	(9)	(3)	-
PBT	319	497	-36%
Taxes	98	59	66%
Taxes on exceptional item	(2)	23	-106%
NET PROFIT BEFORE MINORITY INTEREST	223	415	-46%
Minority interest	87	106	-17%
Minority interest on exceptional item	-	(4)	-
NET PROFIT FOR THE PERIOD	136	313	-57%
EPS Rs.	1.1	2.6	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	144	335	-57%
Exceptional item, net of taxes	(8)	(22)	-66%
NET PROFIT FOR THE PERIOD	136	313	-57%
<i># Licensing Income</i>	15	175	
<i>* Gross Research & Development expenses</i>	228	356	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 24	Q3 FY 24	Variance %
INCOME			
Generics	719	703	2%
Biosimilars	2,358	2,483	-5%
Novel Biologics	-	-	100%
Research services	917	854	7%
Inter-segment	(76)	(86)	-12%
Revenue from operations #	3,917	3,954	-1%
Other income	49	566	-91%
TOTAL REVENUE	3,966	4,519	-12%
EXPENDITURE			
Material & Power costs	1,417	1,320	7%
Staff costs	532	555	-4%
Research & Development expenses*	246	329	-25%
Other expenses	806	823	-2%
Manufacturing, staff & other expenses	3,001	3,027	-1%
EBITDA	964	1,492	-35%
Interest & Finance charges	227	267	-15%
Depreciation & Amortisation	407	415	-2%
Share of loss / (profit) in JV / Associate, net	3	24	-89%
PBT BEFORE EXCEPTIONAL ITEM	328	787	-58%
Exceptional item, Net	(9)	21	-100%
PBT	319	808	-61%
Taxes	98	53	86%
Taxes on exceptional item	(2)	2	-165%
NET PROFIT BEFORE MINORITY INTEREST	223	753	-70%
Minority interest	87	90	-3%
Minority interest on exceptional item	-	3	-
NET PROFIT FOR THE PERIOD	136	660	-79%
EPS Rs.	1.1	5.5	
NET PROFIT BEFORE EXCEPTIONAL ITEM	144	644	-78%
Exceptional item	(8)	16	
NET PROFIT FOR THE PERIOD	136	660	-79%
<i># Licensing Income</i>	15	5	
<i>* Gross Research & Development expenses</i>	228	332	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	FY 24	FY 23	Variance %
INCOME			
Generics	2,799	2,765	1%
Biosimilars	8,824	5,584	58%
Novel Biologics	-	19	-
Research services	3,489	3,193	9%
Inter-segment	(356)	(387)	-8%
Revenue from operations #	14,756	11,174	32%
Other income	866	376	130%
TOTAL REVENUE	15,621	11,550	35%
EXPENDITURE			
Material & Power costs	5,287	4,078	30%
Staff costs	2,137	2,004	7%
Research & Development expenses*	1,154	1,119	3%
Other expenses	2,879	1,461	97%
Manufacturing, staff & other expenses	11,457	8,662	32%
EBITDA	4,164	2,888	44%
Interest & Finance charges	974	419	133%
Depreciation & Amortisation	1,569	1,113	41%
Share of loss / (profit) in JV / Associate, net	84	167	100%
PBT BEFORE EXCEPTIONAL ITEM	1,537	1,189	29%
Exceptional item, Net	(12)	(291)	-
PBT	1,525	897	70%
Taxes	231	176	31%
Tax expense on adoption of new tax regime - exceptional	-	107	
Taxes on exceptional item	(3)	(29)	-100%
NET PROFIT BEFORE MINORITY INTEREST	1,298	643	102%
Minority interest	276	224	23%
Minority interest on exceptional item	(1)	(44)	-
NET PROFIT FOR THE PERIOD	1,022	463	121%
EPS Rs.	8.5	3.9	
NET PROFIT BEFORE EXCEPTIONAL ITEM	1,030	787	31%
Exceptional item, net of taxes	(8)	(217)	
Tax expense on adoption of new tax regime - exceptional	-	(107)	
NET PROFIT FOR THE PERIOD	1,022	463	121%
# Licensing Income	193	206	
* Gross Research & Development expenses	1,161	1,195	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	Mar 31, 2024	March 31, 2023
ASSETS		
Non-current assets		
(a) Property, plant and equipment	7,418	7,277
(b) Capital work-in-progress	3,985	2,588
(c) Right-of-use assets	575	258
(d) Goodwill	16,372	16,136
(e) Other intangible assets	6,279	5,796
(f) Intangible assets under development	4,008	4,730
(g) Investment in associates and a joint venture	-	138
(h) Financial assets		
Investments	684	605
Derivative assets	266	145
Other financial assets	147	1,083
(i) Income tax asset, net	413	354
(j) Deferred tax asset, net	317	301
(k) Other non-current assets	428	298
Non-current assets	40,892	39,709
Current assets		
(a) Inventories	4,944	4,244
(b) Financial assets		
Investments	316	1,327
Trade receivables	6,231	3,573
Cash and cash equivalents	1,234	1,324
Other bank balances	1,025	1,077
Derivative assets	138	70
Other financial assets	577	132
(c) Other current assets	715	588
Current assets	15,180	12,335
TOTAL - ASSETS	56,072	52,044
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	19,183	17,267
Equity attributable to owners of the Company	19,783	17,867
Non-controlling interests	5,491	4,622
Total Equity	25,274	22,489
Non-current liabilities		
(a) Financial liabilities		
Borrowings	12,932	15,291
Lease liabilities	492	209
Derivative liabilities	-	26
Other financial liabilities	1,073	4,620
(b) Other non-current liabilities	392	290
(c) Provisions	311	227
(d) Deferred tax liability, net	238	382
Non-current liabilities	15,438	21,045
Current liabilities		
(a) Financial liabilities		
Borrowings	2,797	2,480
Lease liabilities	55	39
Trade payables	6,272	3,842
Derivative liabilities	1	59
Other financial liabilities	5,001	608
(b) Other current liabilities	277	1,108
(c) Provisions	777	149
(d) Income tax liability, net	180	225
Current liabilities	15,360	8,510
TOTAL - EQUITY AND LIABILITIES	56,072	52,044